WGS GeneDx Holdings Corp - Ordinary Shares - Class A
3,684
$19.72
$0.27
(1.35%)
| Watchers | 3,684 |
| 52-Wk Low | $1.16 |
| 52-Wk High | $24.40 |
| Market Cap | $522.76M |
| Volume | 238,124.00 |
| 52-Wk High | $24.40 |
| 52-Wk Low | $1.16 |
GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024Globe Newswire • about 2 months ago
STAMFORD, Conn., April 04, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results...
Share to Feed
In a report released today, Daniel Brennan from TD Cowen maintained a Buy rating on GeneDx Holdings (WGS Research Report), with a price target of...
In recent trading, shares of GeneDx Holdings Corp (WGS) have crossed above the average analyst 12-month target price of 9.12, changing hands for 9.46/share. When a stock reaches the target...
This indicator may be signaling that WGS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at...
STAMFORD, Conn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company...
In recent trading, shares of GeneDx Holdings Corp (WGS) have crossed above the average analyst 12-month target price of 7.38, changing hands for 8.21/share. When a stock reaches the target...
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on GeneDx Holdings (WGS Research Report) and Glaukos...
Full Year 2024 Revenue Guidance Set Between $220M and $230MRelated Stocks: WGS...
GeneDx Holdings Corp. 2023 Q4 - Results - Earnings Call Presentation...